|ArGentis Seeks More Funding After Obtaining Patent for ARG201 Therapy|
|Monday, 07 June 2010 11:08|
ArGentis Pharmaceuticals LLC has received a patent for its scleroderma therapy while finalizing plans for a Phase IIb trial for the treatment known as ARG201.
The patent comes nearly two years after it was developed by University of Tennessee Health Science Center researchers Arnold Postlethwaite and Andrew Kang and acquired by ArGentis. ArGentis, a Memphis-based specialty biopharmaceutical company, began the patent process and Phase I trials of ARG201 in 2008.
The treatment is for systemic sclerosis, a form of scleroderma, a widespread connective tissue disease that affects the skin, blood vessels, muscles and internal organs. The disease affects about 100,000 people in the U.S. If ARG201 proves successful through its trial, it would become one of the first therapies for patients who have had the disease between three and 10 years, says Ted Townsend, COO of ArGentis.
“This is an unmet medical need and it would be first in class from a commercialization standpoint,” he says.
Source: Memphis Business Journal